ECSP045039A - Composiciones de disgregación intraoral organolepticamente aceptables - Google Patents

Composiciones de disgregación intraoral organolepticamente aceptables

Info

Publication number
ECSP045039A
ECSP045039A ECSP045039A ECSP045039A EC SP045039 A ECSP045039 A EC SP045039A EC SP045039 A ECSP045039 A EC SP045039A EC SP045039 A ECSP045039 A EC SP045039A
Authority
EC
Ecuador
Prior art keywords
compositions
intraoral
disgregation
organoleptically acceptable
organoleptically
Prior art date
Application number
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045039A publication Critical patent/ECSP045039A/es

Links

Abstract

La presente invención se refiere a composiciones farmacéuticas de disgregación intraoral que contienen un fármaco organolépticamente inaceptable como ingrediente activo, y a procesos para preparar dichas composiciones.
ECSP045039 2001-09-26 2004-03-26 Composiciones de disgregación intraoral organolepticamente aceptables ECSP045039A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33535601P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
ECSP045039A true ECSP045039A (es) 2004-04-28

Family

ID=40435086

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP045039 ECSP045039A (es) 2001-09-26 2004-03-26 Composiciones de disgregación intraoral organolepticamente aceptables

Country Status (1)

Country Link
EC (1) ECSP045039A (es)

Similar Documents

Publication Publication Date Title
ECSP083351A (es) Composiciones farmacéuticas
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
GEP20074079B (en) Oral dosage form containing phosphor diesterase inhibitor-4 as an active ingredient and polyvinylpyrrolidone as excipient
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
ECSP045029A (es) Composiciones de valdecoxib de disgregación intraoral
MY149623A (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
HN2002000247A (es) Derivados de sulfonamida
BR0015188A (pt) Composições farmacêuticas
HK1096034A1 (en) A solid dosage form comprising a fibrate
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
CR8371A (es) Formulaciones de medicamento que contienen saborizantes con mejores propiedades farmaceuticas
SE0300831D0 (sv) New formulations and use therof
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
EA201101119A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
BR0306843A (pt) Formulações sedativas de não-benzodiazepina
DE60111503D1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
ECSP045039A (es) Composiciones de disgregación intraoral organolepticamente aceptables